-
2023-508308-40-00
5
2021-07-30
Metastatic (stage IV) squamous or nonsquamous non-small cell lung canc
-
2023-506962-30-00
5
2021-03-29
Non-alcoholic steatohepatitis (NASH)
-
2024-512028-12-00
4
2021-03-19
Advanced ROS1-positive non-small cell lung cancer
-
2024-515944-22-00
4
2021-01-19
BRAFV600E-mutant metastatic Non-small Cell Lung Cancer
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2022-502611-10-00
5
2020-11-24
Primary Progressive Multiple Sclerosis (PPMS)
-
2024-514104-14-00
4
2020-11-04
Adults subjects with advanced malignant pleural (cohort A) or peritone
-
2023-510455-28-00
5
2020-06-10
Hypereosinophilic Syndrome (HES)
-
2023-509049-11-00
5
2020-01-01
FIGO stage III ovarian cancer who are eligible for primary cytoreducti
-
2024-510626-89-00
5
2019-11-18
Non-Alcoholic Steatohepatitis (NASH)
-
2023-504718-31-00
10
2019-10-19
Moderately to Severely Active Ulcerative Colitis
-
2024-515616-47-00
5
2019-10-03
Metastatic Renal Cell Carcinoma
-
2023-507886-25-00
4
2019-09-27
Previously untreated and symptomatic patients with histologically prov
-
2023-505810-12-00
5
2019-09-03
Lower limb spasticity
-
2024-515946-17-00
5
2019-07-22
Non Small Cell Lung Cancer
-
2023-509305-68-00
5
2019-05-16
Pulmonary arterial hypertension (PAH)
-
2024-511850-34-00
9
2019-01-02
Previously untreated locally recurrent inoperable or metastatic triple
-
2023-504820-24-00
5
2018-03-21
Neoadjuvant/Adjuvant treatment for participants with Resectable Stage
-
2024-512470-10-00
11
2018-02-02
End-stage Renal disease
-
2024-510704-37-00
5
2017-03-22
ER+/HER2- metastatic breast cancer
-
2024-513078-23-00
4
2016-12-02
breast cancer in young women
-
2024-511040-58-00
6
2016-01-12
non small cell lung cancer
-
2023-510453-41-00
5
2015-10-26
Castration resistant prostate cancer patients metastatic to bone.
-
2024-516198-61-00
5
2013-06-05
Patients with high risk of relapse, ER+ and HER2- primary non-metastat